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ABSTRACT 
G protein coupled receptors (GPCRs) produce pleiotropic effects by their capacity 
to engage numerous signaling pathways once activated. Functional selectivity (also called 
biased signaling), where specific compounds can bring GPCRs to adopt conformations that 
enable selective receptor coupling to distinct signaling pathways, continues to be 
significantly investigated. However, an important but often overlooked aspect of functional 
selectivity is the capability of ligands such as angiotensin II (AngII) to adopt specific 
conformations that may preferentially bind to selective GPCRs structures. Understanding 
both receptor and ligand conformation is of the utmost importance for the design of new 
drugs targeting GPCRs. In this study, we examined the properties of AngII cyclic analogs 
to impart biased agonism on the angiotensin type 1 receptor (AT1R). Positions 3 and 5 of 
AngII were substituted for cysteine and homocysteine residues ([Sar1Hcy3,5]AngII, 
[Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII) and the resulting analogs were evaluated for 
their capacity to activate the Gq/11, G12, Gi2, Gi3, Gz, ERK and β-arrestin (βarr) signaling 
pathways via AT1R. Interestingly, [Sar1Hcy3,5]AngII exhibited  potency and full efficacy 
on all pathways tested with the exception of the Gq pathway. Molecular dynamic 
simulations showed that the energy barrier associated with the insertion of residue Phe8 of 
AngII within the hydrophobic core of AT1R, associated with Gq/11 activation, is increased 
with [Sar1Hcy3,5]AngII. These results suggest that constraining the movements of 
molecular determinants within a given ligand by introducing cyclic structures may lead to 
the generation of novel ligands providing more efficient biased agonism. 
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1. INTRODUCTION 
 The octapeptide hormone angiotensin II (AngII) is the active component of the 
renin-angiotensin system, responsible for controlling blood pressure and water retention 
via smooth muscle contraction and ion transport. It exerts a wide variety of physiological 
effects, including vascular contraction, aldosterone secretion, neuronal activation, and 
cardiovascular cell growth and proliferation. Virtually all the known physiological effects 
of AngII are produced through the activation of the AT1 receptor (AT1R), which belongs 
to the G protein-coupled receptor (GPCR) superfamily [1] and whose structure in complex 
with a selective AT1R antagonist has recently been elucidated [2]. 
The AT1R interacts with Gq/11 leading to the activation of phospholipase C (PLC), 
in turn leading to the formation of diacylglycerol (DAG) and inositol 1,4,5 triphosphate 
(IP3). IP3 binds to the IP3 receptor on the endoplasmic reticulum, whereupon Ca2+ is 
released into the cytosol. Together, Ca2+ and DAG allow the activation of protein kinase C 
(PKC) [3]. Also, AT1R interacts with G12, thereby activating RhoA and ROCK, via 
RhoGEF regulation, leading to cytoskeleton reorganization [4]. Additionally, reports have 
demonstrated that AT1R interacts with Gi, thereby leading to an inhibition of cAMP 
production [5–7]. The AT1R can also activate the ERK1/2 kinase pathway mediated by 
PKC (G protein-dependent) or by EGFR transactivation, which is G protein-independent 
[8,9]. Following receptor activation, G protein-coupled receptor kinases (GRKs) 
phosphorylate the AT1R, facilitating β-arrestin (βarr) recruitment and terminating G 
protein signaling [10]. βarrs are involved in the desensitization and internalization of 
GPCRs [11] but also serve as scaffolds for further GPCR signaling to the MAPK pathway. 
[12]  
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Biased signaling is the ability of a ligand to stabilize a receptor under a particular 
conformation that promotes activation of specific signaling pathways over others [13,14]. 
The therapeutic potential of functional selectivity is increasingly exploited for the design 
of new drugs since some signaling pathways produce beneficial effects while others can 
have harmful consequences. For example, activation of the Gq/11 pathway by AngII may 
cause adverse effects to the failing heart by increasing blood pressure, while βarr 
recruitment can produce a beneficial effect by promoting cardiomyocyte growth, thus 
improving heart performance [15,16]. The therapeutic potential of AT1R signaling via the 
G12 and Gi pathways has yet to be evaluated. 
Based on extensive photolabeling experiments [17], we have demonstrated that the 
conformation of AngII is highly dynamic even when interacting with the AT1R. We have 
also proposed an integrative model of this complex and unveiled structural and dynamical 
determinants that favor Gq/11 or βarr signaling. Of note, we have shown that Gq/11 
signaling is promoted by the opening of a hydrophobic core just above the so-called major 
H-Bond network (MHN) or sodium binding site [18], notably by the insertion in this core 
of the C-terminal Phe8 residue of AngII. In addition, the perturbation of the MHN was 
shown to modulate the signaling outcome. Our model of the dynamical AngII-AT1R 
complex and molecular dynamics simulations also suggest that the backbone of AngII can 
adopt multiple conformations.  
We have recently shown that changes at positions 4 and 8 of AngII can lead to 
biased signaling of the AT1R [19]. To further pursue our understanding of the molecular 
and dynamical basis of functional selectivity, we asked how constraining the AngII 
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backbone and thus limiting its dynamical behavior would impact the signaling pathways 
of the AT1R. Therefore, we synthesized AngII analogs that were substituted at positions 3 
and 5 with either cysteine or homocysteine (Hcy) and cyclised through the formation of a 
disulfide bond. Using this strategy, we synthesized [Sar1Hcy3,5]AngII, 
[Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII. This cyclisation scheme through the 
oxidation of the sulfhydryl group has the advantage of limiting the changes in 
physiochemical properties and bulkiness of the cycle. Note that previous work has shown 
that cyclisation through these side-chains of AngII led to compounds that can still bind and 
elicit Gq/11 activation [20,21]. However, the impact on the biased signaling has not been 
characterized. Here, we investigate the impact of restraining the conformation of AngII on 
the binding and functional selectivity of the AT1R by measuring the Gq, G12, Gi2, Gi3, 
Gz, ERK and βarr signaling pathways. We then performed molecular dynamics simulations 
to evaluate the impact of AngII cyclic analogs on the conformational landscape of the 
AT1R. 
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2. MATERIALS AND METHODS 
2.1 Materials 
Culture media, trypsin, FBS, penicillin, and streptomycin were from Wisent (St-
Bruno, Qc, Canada). OPTI-MEM was from Invitrogen Canada Inc. (Burlington, ON). 
Polyethyleneimine (PEI) was from Polysciences (Warrington, PA). Go6983 and 
PD168393 were from EMD Millipore (Missisauga, ON).  125I-AngII (specific radioactivity 
~1000 Ci/mmol) was prepared with Iodo-GEN® (Perbio Science, Erembodegem, 
Belgium) as reported previously [22]. 
 
2.2 Peptide synthesis 
 Peptides were synthesized by manual solid-phase peptide synthesis using Fmoc-
protected strategy on Wang resin (Fmoc-protected amino acids and resin were purchased 
from Novabiochem, Missisauga, ON). Peptides were cleaved with 95% TFA adding EDT 
and TLS as scavengers. The crude peptides were then cyclized in 2 M (NH4)2CO3, pH 6.5, 
under constant agitation for 4 h at room temperature. Peptides were then purified on a 
preparative HPLC mounted with a C18 column and using a 10–35% gradient of acetonitrile 
containing 0.05% TFA. Fractions were analysed on an analytical HPLC mounted with a 
C18 column and using a 5–95% acetonitrile gradient containing 0.05% TFA. Pure fractions 
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were pooled, lyophilized, and stored at -20 °C in a dry environment until further use.  The 
pure peptides were characterized on UPLC-MS and showed purity >95%. Structure of the 
compounds and UPLC-MS spectra are available through Figshare at doi: 
10.6084/m9.figshare.6108440. 
 
2.3 Constructs 
The cDNA clone for the human AT1R was kindly provided by Dr. Sylvain Meloche 
(University of Montréal). The AT1R-GFP10 construct was built by inserting the GFP10 
sequence at the C-terminus of the AT1R, joined by a linker sequence (GSAGT) using the 
In-Fusion® PCR cloning system (Clontech Laboratories, Mountain View, CA) as 
recommended by the manufacturer. The RLucII-βarr1, RLucII-βarr2, Gα12-RLucII, Gαi2-
RlucII, Gαi3-RlucII, Gz-RlucII, Gβ1, Gγ1-GFP10 and Gγ2-GFP10 constructs were kindly 
provided by Dr. Michel Bouvier (University of Montréal). All constructs were confirmed 
by automated DNA sequencing. 
 
2.4 Cell culture and transfection 
Human embryonic kidney 293 (HEK293) cells were maintained in DMEM medium 
supplemented with 10% FBS, 100 IU/ml penicillin, and 100 µg/ml streptomycin at 37°C 
in a humidified 5% CO2 atmosphere. HEK293 cells stably expressing the AT1R were 
maintained in medium containing 0.5 mg/mL G418. For the βarr recruitment assays, 
HEK293 cells (3 Í 106 cells) were transiently transfected with 8700 ng of AT1R-GFP10 
and either 300 ng of RlucII-βarr1 or 300 ng of RlucII-βarr2 using linear polyethylenimine 
(1 mg/ml) (PEI:DNA ratio 4:1). For G12 activation assays, HEK293 cells (3 Í 106 cells) 
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were transiently cotransfected with the following constructs: 3000 ng of AT1R, 600 ng 
Gα12-RLucII, 3000 ng Gγ1-GFP10 and 1800 ng Gβ1, using linear polyethylenimine 
(PEI:DNA ratio 4:1). For Gi2 and Gi3 activation assays, HEK293 cells (3 Í 106 cells) were 
transiently cotransfected with the following constructs: 3000 ng of AT1R, 600 ng Gαi2-
RLucII or Gαi3-RLucII, 3000 ng Gγ2-GFP10 and 3000 ng Gβ1, using linear 
polyethylenimine (PEI:DNA ratio 3:1). For Gz activation assays, HEK293 cells (3 Í 106 
cells) were transiently cotransfected with the following constructs: 3000 ng of AT1R, 600 
ng Gz-RLucII, 3000 ng Gγ1-GFP10 and 3000 ng Gβ1, using linear polyethylenimine 
(PEI:DNA ratio 3:1). 
 
2.5 Binding Experiments 
HEK293 cells stably expressing the AT1R were washed once with PBS and 
submitted to one freeze-thaw cycle. These broken cells were then gently scraped into 
washing buffer (25 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM MgCl2), centrifuged at 
2500 × g for 15 min at 4 °C, and resuspended in binding buffer (25 mM Tris-HCl, pH 7.4, 
100 mM NaCl, 5 mM MgCl2, 0.1% bovine serum albumin, 0.01% bacitracin). Dose 
displacement experiments were done by incubating broken cells (20–40 μg of protein) for 
1 h at room temperature with 0.8 nM 125I-AngII as tracer and increasing concentrations of 
AngII or analogs. Bound radioactivity was separated from free ligand by filtration through 
GF/C filters presoaked for at least 3 hours in binding buffer. Receptor-bound radioactivity 
was evaluated by γ counting. Results are presented as means ± S.D. The Ki values in the 
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displacement studies were determined from the IC50 values using the Cheng-Prusoff 
equation. 
 
2.6 Measuring inositol-1 phosphate production 
We used the IP-One assay (Cisbio Bioassays, Bedford, MA) to measure inositol 1-
phosphate (IP1) levels. Necessary dilutions of each analog were prepared in stimulation 
buffer (10 mM Hepes, 1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 
mM glucose, 50 mM LiCl, pH 7.4). HEK293 cells stably expressing the AT1R were 
washed with PBS at room temperature, then trypsinized and distributed at 15 000 cells/well 
(7 μl) in a white 384-well plate in stimulation buffer. Cells were stimulated at 37°C for 30 
min with increasing concentrations of AngII or analogues. Cells were then lysed with the 
lysis buffer containing 3 μl of IP1 coupled to the d2 dye. After addition of 3 μl of anti-
IP1 cryptate terbium conjugate, cells were incubated for 1 h at room temperature under 
agitation. FRET signal was measured using a TECAN M1000 fluorescence plate reader 
(TECAN, Austria). 
 
2.7 BRET-based biosensor assays 
After 48 h post-transfection, cells were washed with PBS and resuspended in BRET 
buffer (10 mM Hepes, 1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 
mM glucose, pH 7.4). For the βarr recruitment assays, the proximity of fusion protein 
RLucII-βarr to the reporter AT1R-GFP10 was evaluated. Upon stimulation, RLucII-βarr 
was recruited to the AT1R-GFP10 fusion protein, whereby the BRET signal was increased. 
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For the G12, Gi2, Gi3 and Gz activation assays, the biosensor measures the proximity of 
the fusion protein RLucII-Gα to GFP10-Gγ. Upon activation, both RLuc-Gα and GFP10-
Gγ move away from each other, resulting in a decrease in the measured BRET. For all 
BRET assays, cells transfected with the appropriate constructs were stimulated with the 
indicated ligands in 96-well white plates (50 000 cells/well). Cells were stimulated for 
either 1 min (Gi2 and Gi3), 5 minutes (Gz) or 8 minutes (G12), and then coelentherazine 
400A was added at a final concentration of 5 uM. All BRET signals were measured using 
a TECAN M1000 fluorescence plate reader. The BRET ratio was calculated as the GFP10 
emission over luminescence emission. Ligand-promoted BRET ratio was calculated by 
subtracting the BRET ratio under basal conditions from the BRET ratio upon maximal 
stimulation. All data were expressed as a percentage of maximal AngII response. 
 
2.8 ERK1/2 activation assay 
ERK1/2 activation was measured using the ERK1/2 AlphaScreen Surefire kit 
(PerkinElmer, Waltham, MA). HEK293 cells stably expressing the AT1R were seeded into 
96-well plates at a density of 125 000 cells/well. After 24 h, cells were starved for at least 
16 h in phenol red-free media before stimulation. We previously showed that, in HEK293 
cells stably expressing the AT1R, the two main pathways leading to the activation of 
ERK1/2 by AngII were dependent on the activity of PKC and on the activity of EGFR. In 
the presence of both the EGFR tyrosine kinase inhibitor PD168393 and the PKC inhibitor 
Go6983 no significant ERK1/2 activity could be detected. Therefore, upon treatment with 
PD168393, the ERK response was PKC-dependent with a maximal response obtained after 
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2 min, while upon treatment with Go6983, the ERK response was EGFR-dependent with 
a maximal response obtained after 5 min [19]. Where specified, Go6983 (1 uM) or 
PD168393 (250 nM) were added 30 min before stimulation. For concentration-response 
experiments, cells were stimulated with increasing concentrations of indicated ligand. 
Stimulation of cells was terminated by the addition of lysis buffer to each well. The plate 
was then agitated at room temperature for 10 min and 4 µl of lysate was transferred to 384-
well ProxiPlates (PerkinElmer, Waltham, MA) and 5 ul of the assay reaction mix was 
added to each well (reaction buffer : activation buffer : donor beads : acceptor beads  = 120 
: 40 : 1 : 1).  The plate was then incubated in the dark at room temperature for 24 h under 
agitation and the signal was measured with an Enspire alpha reader (PerkinElmer, 
Waltham, MA) using standard AlphaScreen settings. All data were expressed as a 
percentage of maximal AngII-induced ERK1/2 phosphorylation. 
 
2.9 Data analysis 
Binding data were analyzed with Prism version 7.0 (GraphPad Software, San Diego 
CA), using a one-site binding hyperbola nonlinear regression analysis. Transduction ratios 
and bias factors were calculated based on the method of Kenakin [23], as described in detail 
by van der Westhuizen et al [24]. Transduction ratios [log(t/KA)] were first derived using 
the operational model equation in GraphPad Prism. The transduction ratio is an assessment 
of the effect (potency and efficacy) of a compound on receptor conformation and the 
subsequent ligand-receptor interaction with downstream effectors. In order to assess true 
ligand bias, system and observational bias which may be present owing to the different 
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sensitivities of the assays used must be eliminated by comparing ligand activity at a given 
signaling pathway to that of a reference agonist. AngII, which yielded similar potencies 
and maximally activated all the pathways, was the reference compound. By subtracting 
log(t/KA) of AngII to the log(t/KA) value of each analog for a given pathway, a within-
pathway comparison was first established, yielding Δlog(t/KA). Finally, between-pathway 
comparisons were achieved for a given ligand in the form of ΔΔlog(t/KA) and the bias 
factor BF. ΔΔlog(t/KA) were calculated by substracting Δlog(t/KA) values of one signaling 
pathway from the Δlog(t/KA) of the signaling pathway to which it is compared. BF values 
are the base 10 values of ΔΔlog(t/KA) and are the actual bias factors. 
Statistical analyses of the ΔΔlog(t/KA) values were performed with Prism version 
7.0 using the Two-tailed unpaired student t-test. A value was considered statistically 
significant when P < 0.05. 
 
2.10 Numbering of residues 
In order to facilitate comparison of the same position of an amino acid across 
multiple GPCRs, residues in transmembrane domains (TMD) of the AT1R were given two 
numbering schemes. First, residues were numbered according to their positions in the 
AT1R primary structure. Second, residues were also indexed according to their position 
relative to the most conserved residue in each TMD in which they are located. By 
definition, the most conserved residue was assigned the position index “50” e.g. in TM6, 
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P255 is the most conserved residue and was designated P255(6.50), whereas the upstream 
residue was designated I254(6.49) and the downstream residue H256(6.51). 
 
2.11 Molecular dynamic simulations  
The GROMACS software suite [25,26] was used to prepare and run the simulations 
in a similar fashion to previous work [18]. The AT1R was inserted in a lipid bilayer 
consisting of 128 molecules of POPC using the g_membed tool in GROMACS. The 
membrane-receptor system was solvated with the SPC water model [27]. Sodium and 
chloride ions were added at random positions, replacing water molecules, to keep the net 
charge of the system at 0 and to have an approximate salt concentration of 150 mM. The 
ffg54a7 force field and the corresponding POPC parameters included in the GROMACS 
installation were used for the calculations [28,29]. A first equilibration phase was 
performed under NPT conditions for 1 ns while gradually heating the system for the first 
500 ps to reach the desired temperature of 310 K. During this first phase, phosphate head 
group of the POPC molecules were restrained. This was followed by a second equilibration 
under NPT conditions for 100 ns with the pressure set at 1 bar, without the restraints on the 
POPC molecules. Such long equilibration was performed to allow proper equilibration of 
the lipids after embedding a protein in the membrane [30]. These equilibration times were 
reduced to 100 ps for the first phase and 1 ns for the second phase for all other simulations 
that were generated using the originally equilibrated system. The position of all heavy 
atoms of the receptor and ligand were restrained during equilibration. Unrestrained MD 
simulations were run in 5 fs steps for 1 μs of total MD simulation time, in the form of 10 
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simulations of 100 ns in length for each receptor. Using multiple shorter MD trajectories 
rather than a single long one prevents known problems that can occur with long trajectories 
in current force fields [31]. Random seed was used for velocity generation during the initial 
equilibration phase. Thus, all MD trajectories of a given system (e.g. AngII-AT1R 
complex) share the same initial conformation and velocities at the start of the production 
MD runs. Divergence in the multiple trajectories is the result of the inherent imprecision 
of the calculations, which originate from the single-precision floating point format used as 
well as differences in the order of addition of force caused by dynamic load balancing 
((a+b)+c ≠ a+(b+c) due to rounding-off). The simulations were run under periodic 
boundary conditions at constant temperature (310 K) and pressure (1 bar) using the Nose-
Hoover thermostat [32,33] with τT = 2 ps and the Parrinello-Rahman barostat with τP = 5 
ps, respectively. Simulation data were saved every 50 ps, for a total of 20001 frames per 
microsecond. 
 
2.12 Trajectory analysis  
 MD trajectory outputs from GROMACS were converted to PDB files for visual 
inspection with PyMOL [34] and to compressed XTC trajectory files for other analyses. 
Distance between atoms or group of atoms were measured with the g_dist tool within 
GROMACS. One-dimensional probability distributions were calculated using the 
g_analyze tool. Two-dimensional probability density functions were calculated using 
g_sham with a grid of 50 x 50 bins and nlevels = 200. 
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3. RESULTS 
3.1 Binding properties of cyclic AngII analogs  
We evaluated the binding properties of three cyclic Ang II analogs. 
[Sar1Hcy3,5]AngII showed binding affinity in the low nanomolar range (Kd = 2.7 nM) 
comparable to that of AngII (Kd = 0.9 nM) whereas cyclic analogs [Sar1Cys3Hcy5]AngII 
(Kd = 324 nM) and [Sar1Cys3,5]-AngII (Kd = 674 nM) showed low binding affinities (Table 
1).  
 
3.2 Evaluation of potency and efficacy of cyclic analogs on AT1R signalling pathways 
The potency and efficacy of the cyclic AngII analogs were then evaluated in 9 
different signaling pathways. We first measured activation of the Gq/11 pathway by 
measuring IP1 production (Fig. 1A). For this assay, the AngII dose-response curve revealed 
a maximal production of 3352 nM IP1 (efficacy normalized to 100%) with a half-maximal 
response (EC50) obtained at a concentration of 4 nM. The [Sar1Hcy3,5]AngII dose-response 
curve (Fig. 1A) showed an efficacy of 78% with a potency of 51 nM for Gq/11 activation. 
[Sar1Cys3Hcy5]AngII (Fig. 1A) had an efficacy of 74% with a potency of 1.5 µM. 
[Sar1Cys3,5]AngII (Fig. 1A) was also a partial agonist with an efficacy of 60% and a 
potency of 2.9 µM. The AngII dose-response curve for G12 activation (Fig. 1B) revealed 
a maximal ligand-promoted BRET ratio of 0.091 (efficacy normalized to 100%) with an 
EC50 of 6.6 nM. The [Sar1Hcy3,5]AngII dose-response curve (Fig. 1B) showed a full 
efficacy of 101% with a potency of 8.0 nM. [Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII  
(Fig. 1B) were partial agonists with low efficacies of 37% and 42% and low potencies of 
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125 nM and 949 nM respectively. We next evaluated the activation of signalling pathways 
from the Gi family, namely Gi2, Gi3 and Gz. For Gi2, the AngII dose-response curves 
showed a maximal ligand-promoted BRET ratio of 0.044 with an EC50 of 2.2 nM (Fig. 1C). 
The [Sar1Hcy3,5]AngII dose-response curve (Fig. 1C) showed a full efficacy of 100% with 
a potency of 3.7 nM. [Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII (Fig. 1C) were partial 
agonists with efficacies of 64% and 53% and potencies of 92 nM and 58 nM respectively. 
For Gi3, the AngII dose-response curves showed a maximal ligand-promoted BRET ratio 
of 0.099 with an EC50 of 1.5 nM (Fig. 1D). The [Sar1Hcy3,5]AngII dose-response curve 
(Fig. 1D) showed a full efficacy of 100% with a potency of 2.5 nM. [Sar1Cys3Hcy5]AngII 
and [Sar1Cys3,5]AngII  (Fig. 1D) showed efficacies of 92% and 73% and potencies of 62 
nM and 67 nM respectively. For Gz, the AngII dose-response curves showed a maximal 
ligand-promoted BRET ratio of 0.061 with an EC50 of 1.5 nM (Fig. 1E). The 
[Sar1Hcy3,5]AngII dose-response curve (Fig. 1E) showed a full efficacy of 97% with a 
potency of 7.4 nM. [Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII  (Fig. 1E) showed 
efficacies of 70% and 64% and potencies of 29 nM and 18 nM respectively. The AngII 
dose-response curve for βarr1 recruitment showed a maximal ligand-promoted BRET ratio 
of 0.077 (efficacy normalized to 100%) with an EC50 of 4.1 nM (Fig. 1C). The AngII dose-
response curve for βarr2 recruitment showed a maximal ligand-promoted BRET ratio of 
0.095 (efficacy normalized to 100%) with an EC50 of 3.3 nM (Fig. 1C). The 
[Sar1Hcy3,5]AngII dose-response curves (Fig. 1C and Fig. 1D) for βarr1 and βarr2 
recruitment showed full efficacies of 97% and 100% with potencies of 4.9 nM and 4.7 nM 
respectively. [Sar1Cys3Hcy5]AngII (Fig. 1C and Fig. 1D) was a partial agonist for βarr1 
and βarr2 recruitment with efficacies of 46% and 70% and low potencies of 183 nM and 
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222 nM respectively. [Sar1Cys3,5]AngII (Fig. 1C and Fig. 1D) was also a partial agonist for 
βarr1 and βarr2 recruitment with efficacies of 53% and 61% and low potencies of 891 nM 
and 980 nM respectively. The AngII dose-response curve for PKC-dependent ERK 
activation (Fig. 1E), as determined in the presence of the EGFR inhibitor PD168393 
revealed a maximal response of 52 703 luminescence arbitrary units (efficacy normalized 
to 100%) with an EC50 of 4.8 nM. The AngII dose-response curve for EGFR-dependent 
ERK activation (Fig. 1F), in the presence of PKC inhibitor Go6983 revealed a maximal 
response of 66 302 luminescence arbitrary units (efficacy normalized to 100%) with an 
EC50 of 3.2 nM. The [Sar1Hcy3,5]AngII dose-response curve (Fig. 1E and Fig. 1F) for PKC-
dependent and EGFR-dependant ERK activation showed a full efficacy of 107% and 99% 
with a potency of 13 nM and 10 nM respectively. [Sar1Cys3Hcy5]AngII and 
[Sar1Cys3,5]AngII (Fig. 1E) were partial agonists of the PKC-dependent ERK activation 
with efficacies of 72% and 55% with low potencies of 234 nM and 280 nM respectively. 
[Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII (Fig. 1F) were also partial agonists of the 
EGFR-dependent ERK activation with efficacies of 85% and 62% with low potencies of 
299 nM and 187 nM respectively. All these results are summarized in Table 2. 
 
3.3 Quantification of ligand bias 
 3.3.1 ‘Within-pathway’ comparison of ligand efficacies 
Variations in the potencies and efficacies of AngII cyclic analogs towards the 
different signaling pathways were observed (Table 2). This suggests the presence of 
signaling bias. In order to clearly establish whether an analog was biased towards one 
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pathway over the others, the bias factors were determined for each analog and for all the 
signaling pathways studied. Transduction ratios [log(t/KA)] for the cyclic analogs were 
first derived using the operational model. The log(t/KA) of the reference compound AngII 
was then subtracted from the log(t/KA) value of each analog for a given pathway, yielding 
Δlog(t/KA) as a ‘within-pathway’ comparison for each signaling pathway. The Δlog(t/KA) 
value is indicative of how well a given signaling pathway can be activated by a ligand, 
where a value of 0 indicates that a given ligand activates a pathway to the same degree as 
the reference compound, a positive value indicating that the ligand more strongly activates 
the signaling pathway than the reference compound and an increasingly negative value 
indicating that the ligand poorly activates the signaling pathway, if at all. Using these 
values, every signaling pathway was represented on a radar plot, adapted from the ‘web of 
efficacy [35,36] (Fig.2). The log(t/KA) mean value of AngII for each pathway evaluated 
was 8.39. [Sar1Hcy3,5]AngII had log(t/KA) values ranging from 7.92 to 8.33, with 
Δlog(t/KA) values ranging from -0.62 to 0.01, for each pathway evaluated with the 
exception of the Gq pathway (Table 3 and Fig 2A). For the Gq pathway, the calculated 
log(t/KA) was 6.79, with a Δlog(t/KA) of -1.70, indicating a decreased capacity of this 
analog to activate the Gq pathway (Table 3 and Fig 2A). As for [Sar1Cys3Hcy5]AngII (Fig. 
2B) and [Sar1Cys3,5]AngII (Fig. 2C), log(t/KA) values ranged from 4.76 to 6.27 in all of 
the signaling pathways, with Δlog(t/KA) values ranging from -3.30 to -2.10 (Table3), 
indicating that both analogs were poor activators of every signaling pathway evaluated. 
3.3.2 Quantification of ‘between-pathway’ bias  
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Ultimately, a ‘between-pathway’ comparison was achieved for a given ligand in the 
form of ΔΔlog(t/KA), which led to the actual bias factor (10(ΔΔlog(t/KA))) (Tables 4 and 5). 
Table 4 shows that the bias of [Sar1Hcy3,5]AngII toward βarr1 and βarr2 over Gq/11 was 
36-fold and 44-fold respectively. The bias of [Sar1Hcy3,5]AngII toward PKC-ERK and 
EGFR-ERK was 20-fold and 12-fold respectively whereas the bias toward G12 was 51-
fold. For [Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII the bias factors were less 
pronounced.  
3.3.3 Effect on rank order of potency 
 We have performed a rank order of potency analysis for the affinity as well as for 
each pathway presented in this study (Table 6). Our results show that the endogenous 
reference ligand AngII was always the most powerful agonist for all signaling pathways 
examined. [Sar1Hcy3,5]AngII was the most powerful macrocyclic AngII analog of the 
described series and shows a potency equal to the AngII in all of the signaling pathways 
except for Gq/11, and ERK were this ligand is less potent than the reference compound. 
[Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII are usually ranked in this order for both 
affinity and signaling activity except for three signaling pathways, Gz, βarr1, and G12. For 
Gz and βarr1 pathways, both ligands are shown to be equally potent however, there is an 
inversion in the rank order of potency for the G12, [Sar1Cys3,5]AngII being more potent 
than [Sar1Cys3Hcy5]AngII to trigger a G12 response. 
These rank order of potency results confirm that there is a change in agonistic properties 
of the macrocyclic AngII analogs leading to ligand bias and that the difference observed 
is not related to a loss of affinity of the ligands at AT1R. 
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3.4 Molecular dynamics simulations of liganded-AT1R complexes  
3.4.1 Modeling of ligand structures 
 In order to better understand how the conformational restriction conferred by the 
intramolecular disulfide bond of the AngII cyclic analogs affects the ligand binding 
conformation and the conformational landscape of the receptor, we performed molecular 
dynamic (MD) simulations. Initially, we modeled the structure of all three cyclic ligands 
in water (Fig. 3A) in a 10 ns MD simulation. These simulations were then used to evaluate 
the distance between the Cβ atoms of the residues in positions 3 and 5 (Fig. 3B). The MD 
simulation of [Sar1Hcy3,5]AngII showed an average distance between the Cβ atoms of Hcy3 
and Hcy5 of 0.54 ± 0.05 nm. The corresponding distances were 0.48 ± 0.03 nm in the MD 
simulation of [Sar1Cys3HCy5]AngII  and 0.42 ± 0.03 nm in the MD simulation of 
[Sar1Cys3,5]AngII (Fig. 3B), which were below the distances evaluated for AngII. This 
suggests that the cyclic analogs have a more constrained structure in water when compared 
to AngII. 
3.4.2 MD simulations of the AngII-AT1R complexes 
We next generated a complex between AngII and AT1R by docking our previously 
established model of AngII bound to a homology model of the AT1R [17,37] onto the three-
dimensional crystal structure of the AT1R [2]. One microsecond of MD simulation time 
was initially performed on the AngII-AT1R complex in the form of ten trajectories each 
100 ns in length. The trajectories were analyzed to assess whether AngII bound to the AT1R 
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natively adopts conformations compatible with cyclization between residues 3 and 5. To 
do so, we monitored the distribution of the distance between the Cβ atoms of Val3 and Ile5 
(Fig. 4).  Our analysis revealed that the distance between the Cβ atoms ranged from 0.55 
nm to 0.92 nm (Fig. 4A). Furthermore, we observed that AngII adopts a conformation 
where this distance is 0.62 nm or less, permissible for the cyclization of [Sar1Hcy3,5]AngII, 
during 4.9 % of the simulation. However, for both [Sar1Cys3HCy5]AngII and 
[Sar1Cys3,5]AngII, the required distance for cyclization must be shorter. This result 
indicates that AngII can spontaneously adopt conformations that bring the side-chains of 
Val3 and Ile5 in close proximity and that cyclization of AngII through these positions will 
not lead to non-native conformations. To verify that the relatively short simulation time of 
1 µs did not itself introduce bias, the AngII-AT1R complex simulation was thus prolonged 
to 5 µs (10 trajectories of 500 ns) to further sample the conformational space. Prolonging 
the simulations did not reveal any new populations, hence we feel comfortable that the 
short simulation time was sufficient to obtain a meaningful trajectory. Our results suggest 
that the disulfide bond in [Sar1Hcy3,5]AngII biases the AT1R conformational space towards 
structures that are less capable of activating the Gq pathway. We therefore performed the 
same simulation using [Sar1Ile8]AngII, which does not activate Gq upon binding the AT1R 
[19].The probability distribution of the [Sar1Ile8]AngII-AT1R simulation shows a small 
population optimum at d = 0.58 nm, with a second configuration with an optimum at d = 
0.82 nm, as also seen in the AngII-AT1R simulation. During the [Sar1Ile8]AngII-AT1R 
simulation, we observed that the distance between the Cβ of Val3 and Ile5 was less than 
0.62 nm for 17.0 % of the simulation, compared to 4.9 % in the AngII-AT1R simulation.  
3.4.3 MD simulations of the [Sar1Cys3Hcy5]AngII-AT1R complexes 
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To further document the fact that the conformation of the cyclic [Sar1Hcy3,5]AngII 
is detrimental to the stabilization of AT1R conformations capable of activating the Gq 
pathway, we performed 3 molecular dynamics simulations of the [Sar1Hcy3,5]AngII-AT1R 
complex with the cyclic ligand (#C1, #C2 and #C3) together with three AngII-AT1R 
control simulations in which the ligands #L1, #L2 and #L3 have the same corresponding 
starting positions and backbone conformations as #C1, #C2 and #C3 but where Hcy3 and 
Hcy5 where replaced by the native Val3 and Ile5. The distance between the Cβ atoms of 
Val3 and Ile5 (or Hcy3 and Hcy5) were measured in each simulation (Fig. 4B). Predictably, 
the [Sar1Hcy3,5]AngII-AT1R simulations display a narrow distance distribution. 
Simulations #C1 and #C2 feature two population optima at d = 0.54 nm and 0.60 nm and 
simulation #C3 has a single optimum at 0.58 nm. The corresponding simulations of the 
parent AngII-AT1R complexes (# L1, #L2 and #L3) indicate that AngII has the capacity to 
adopt a variety of potentially stable conformations and maintain native conformations with 
a distance of ≤ 0.62 nm between the Cβ atoms of Val3 and Ile5, which was not hindered by 
initial placement of the ligand in the simulations.  
We examined more precisely the conformations adopted by AngII with a focus on 
residues 3 to 5 and noted three recurrent configurations (Fig. 5). We observed a b-strand 
conformation for Val3, Tyr4 and Ile5 of AngII with the distance of about 0.70 nm between 
the Cβ of Val3 and Ile5 as expected in a typical anti-parallel b-sheet. We also observed a g-
turn conformation of the backbone which allows for the positioning of the Cβ atoms of Val3 
and Ile5 within the distance required for the formation of the disulfide bond between two 
homoCys residues. Lastly, an extended backbone conformation with a larger distance (0.8 
nm) was also observed.  
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3.5 Environments explored by the C-terminal Phe8 of AngII and [Sar1Hcy3,5]AngII within 
the AT1R 
To further document the structural and dynamical differences between AngII and 
[Sar1Hcy3,5]AngII in complex with the AT1R we monitored the location and the 
environment of the C-terminal Phe8 residue in each simulation. Phe8 is known to be an 
crucial determinant for AT1R Gq signaling and its substitution with hydrophobic residues 
leads to βarr biased ligands, as is the case with [Sar1Ile8]AngII [19,38,39]. We had 
previously described [37] that the insertion of Phe8 within the hydrophobic core, which we 
ascribed to the activation of Gq, occurs when the distance between Phe8 of AngII and 
residue F772.53 of the AT1R is approximately 0.86 nm or less (Fig. 6). The distance between 
the side chain of Phe8 and the side chain of F772.53 of the AT1R was thus monitored for all 
simulations (Fig. 7). The simulation of the AngII-AT1R complex showed a wide 
distribution of distances with peaks at d = 0.72 nm (Phe8 inside the hydrophobic core) and 
d = 1.10 nm (Phe8 outside the hydrophobic core) (Fig. 7A). The distance was 0.86 nm or 
less for 37.6 % of the AngII-AT1R simulation time. The simulation of the AngII-AT1R 
complex was also prolonged to 5 µs (10 trajectories of 500 ns) from the initial 1 µs (Fig. 
7A). The populations with Phe8 positioned in the hydrophobic core (at d = 0.70 nm) or 
outside the hydrophobic core (at d = 1.10 nm) show similar probabilities but are more well 
defined than in the initial simulation of the AngII-AT1R complex. We also performed a 
simulation using [Sar1Ile8]AngII, that is incapable of activating Gq. This simulation shows 
that position 8 only rarely inserts into the hydrophobic core (Fig. 7A).    
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Simulations in #C1 and #L1 showed (Fig. 7B) that the side-chain of Phe8 of the 
linear peptide is more likely to be in the hydrophobic core than that of the cyclic peptide. 
Simulations #L2, #C2, #L3 and #C3 all favored a distance close to their respective starting 
configurations (Fig. 7B). Interestingly, the probability distribution of #L2 indicates Phe8 
inserted in the hydrophobic core on occasion (d ≤ 0.86 nm for 7.5 % of the simulation) 
while it did not in simulation #C2 (d ≤ 0.86 nm for 0.1 % of the simulation). The probability 
of Phe8 being inserted in the hydrophobic core was slightly higher with the cyclic peptide 
in simulation #C3 than with the linear peptide in #L3 (d ≤ 0.86 nm for 97.1 % in #C3 and 
95.1% in #L3). Combining all three simulations of each ligand, our analysis shows that 
AngII has an increased probability of sampling a transition state (centered at d ≈ 0.90 nm 
on the probability distribution) than does [Sar1Hcy3,5]AngII (Fig 7C). The proportion of 
total population with d ≤ 0.86 nm was also larger when comparing the three linear (#L1, 
#L2 and #L3) simulations (46.7 %) to the three cyclic (#C1, #C2 and #C3) simulations 
(42.5 %). Taken together, the results indicate that [Sar1Hcy3,5]AngII maintains a stable 
conformation with Phe8 inserted in the hydrophobic core, but both this state and the 
transition state are sampled less often than with AngII. 
 
3.6 2D probability distribution functions reveals a link between the conformation of the 
backbone of residues Val3 to Ile5 and the position of side-chain of Phe8 in the AT1R 
In order to evaluate the possible correlation between the structure of the ligand and 
the position of Phe8 relative to the hydrophobic core, we generated two-dimensional (2D) 
probability distribution functions (PDFs). We obtained PDFs where the distance between 
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Phe8 and F772.53 of the AT1R is plotted on the x axis and the distance between the Cb of the 
residues in position 3 and 5 of the ligand is plotted on the y axis (Fig. 8). All initial ligand 
positions are denoted by a star. To facilitate interpretation, 2D PDFs were divided into 
quadrants. The simulation of the AngII-AT1R complex indicates that the ligand can adopt 
g-turn (d < 0.70 on the y axis, bottom quadrants), b-strand (d = 0.70 on the y axis) or 
extended conformations (d > 0.70 on the y axis, top quadrants) with Phe8 either inserted 
within the hydrophobic core (d < 0.86 on the x axis, left quadrants) or excluded from the 
hydrophobic core (d > 0.86 on the x axis, right quadrants) (Fig. 8). For the AngII-AT1R 
complex, we observed that there was a lower probability (dark blue) of AngII to sample a 
distance of d = 0.86 nm on the x axis when in a g-turn conformation (bottom quadrants) 
compared to the higher probability (yellow or green) when AngII is in an extended 
conformation (top quadrants). This indicates that the transition of Phe8 inside or outside of 
the hydrophobic core is facilitated when the ligand is in an extended conformation 
compared to the g-turn conformation. The conformational landscape of the prolonged 
simulation of the AngII-AT1R complex (5 µs) shows one additional small population with 
d > 1.5 nm on the x axis describing a state where Phe8 of AngII is outside the hydrophobic 
core. The prolonged 2D probability distribution also supports the observations derived 
from the 1 µs simulations. When we examined the conformational landscape from the 
simulation of the [Sar1Ile8]AngII-AT1R complex (Fig. 8) we found that the extended 
configuration of the ligand with Ile8 positioned outside of the hydrophobic core is favored 
(top right quadrant). Well-defined populations of the ligand in g-turn conformation are 
observed with Ile8 positioned both in (bottom left quadrant) and out (bottom right 
quadrant) of the hydrophobic core. Furthermore, the conformational landscape shows the 
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g-turn conformation of the ligand (bottom left quadrant) is preferred over the extended 
conformation (top left quadrant) when the distance between Phe8 and F772.53 is below the 
0.86 nm threshold.   
Simulation #C1 of the cyclic ligand shows that the g-turn conformation of the ligand 
is favored. The 2D PDF also shows that the most stable conformation of [Sar1Hcy3,5]AngII, 
is observed when Phe8 is inserted in the hydrophobic core (bottom left quadrant). We also 
observed two populations outside of the hydrophobic core (bottom right quadrant) that 
correspond to the two ligand conformers shown on the one-dimensional probability 
distributions (Fig. 3B). These two conformers have equal population, and correspond to 
ligands that have intermediate conformations between the g-turn and the b-strand. The 
corresponding simulation #L1 using the linear peptide shows a preferred conformation of 
the ligand close to its initial conformation (bottom left quadrant), which is compatible with 
the conformation of the cyclic ligand (Fig. 8). A minor population where the ligand 
maintained Phe8 close to F772.53 while adopting an extended conformation can also be 
observed (top left quadrant). The landscape shows the γ-turn conformation of AngII is 
preferred when Phe8 is outside of the hydrophobic core (bottom right quadrant). These 
simulations illustrate that a conformationally constrained AngII ligand can still access the 
AT1R hydrophobic core leading to Gq activation. The conformational landscape of 
simulation #C2 displays a single population with Phe8 positioned outside of the 
hydrophobic core (bottom right quadrant) while that of the corresponding control 
simulation #L2 shows a similar population but shifted upwards on the y-axis. Simulation 
#C3 displays a single population with Phe8 inside the hydrophobic core (bottom left 
quadrant) (Fig. 8). The corresponding control simulation #L3 shows a population 
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distribution that is wider and shifted upwards on the y-axis compared to #C3, centered close 
to the b-strand conformation but also sampling both the γ-turn and extended conformations 
(Fig. 8). A minor population is observed with Phe8 being out of the hydrophobic core and 
the ligand being in extended configuration (top right quadrant). For both sets of 
simulations #C2/#L2 and #C3/#L3, the favored populations of the ligand were very close 
to their initial conformation, and these ligands were only able to transition into (#C2/#L2) 
or out of (#C3/#L3) the AT1R hydrophobic core with less probability. The results of our 
simulations support the notion that the γ-turn conformation forced by the homoCys-
homoCys disulfide bond present in [Sar1Hcy3,5]AngII lowers the probability of insertion 
of Phe8 into the hydrophobic core compared to unconstrained AngII. 
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4. DISCUSSION 
Ligand bias or functional selectivity is a validated concept that is becoming 
increasingly relevant in the field of pharmacology. It allows for the fine tuning of a cellular 
response by enabling a receptor to adopt a conformation that leads to the activation of 
specific signaling pathways. Development of ligands able to elicit bias could introduce 
selective therapeutic approaches for desired targets by activating pathways responsible for 
beneficial effects without activating pathways that could possibly yield undesired ones 
[13–15]. In this vein, the purpose of this study was to investigate whether constraining the 
conformation of AngII by using analogs that were cyclized at positions 3 and 5 would lead 
to ligand bias and, using molecular dynamics simulations, to understand how such analogs 
interact with the AT1R to allow such a bias. 
We determined that the cyclic ligand [Sar1Hcy3,5]AngII has mild negative bias 
against the Gq pathway, as shown in Fig. 2. Indeed, among the pathways tested, the potency 
and efficacy of this ligand were reduced exclusively on this pathway. As for cyclic ligands 
[Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII, where the ring size is reduced respectively by 
1 and 2 atoms (Fig. 3A), the efficacy and the potency were significantly reduced in all 
pathways evaluated and these ligands showed no significant bias in any pathway tested. 
Previous work has demonstrated that [Sar1Ile8]AngII acts as a biased agonist for G12, βarrs 
and ERK pathways while not activating Gq [19]. Furthermore, both [Sar1Hcy3,5]AngII  and 
[Sar1Ile8]AngII exhibited one of the advantages of functional selectivity of the AT1R by 
only activating the signaling pathway associated with cardiac benefits (βarr) without fully 
activating Gq, responsible for less desirable hypertensive effects [15].  
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The molecular dynamic simulations (Fig. 3B, #L1) show that AngII, in our model 
of the AngII-AT1R complex, has the capacity to adopt a stable g-turn conformation between 
residues Val3 and Ile5 which is very similar to the conformation of the cyclic ligand 
[Sar1Hcy3,5]AngII. However, in the other two control simulations (Fig 9B, #L2 and #L3), 
AngII only transiently adopted this conformation. Thus, while AngII can adopt and 
maintain the g-turn conformation for residues Val3 through Ile5 while bound to AT1R, more 
extended conformations seem favored. As for the other two cyclic analogs, 
[Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII, the distance between the Cβ atoms of the 
residues in positions 3 and 5 was too long for those analogs to adopt conformations that 
were compatible with AngII.  This could explain why the binding affinity of cyclic ligands 
decreases as the number of atoms forming the cycle diminishes. It would be interesting to 
further investigate whether increasing the size of the cycle could lead to compounds with 
better affinities or functional selectivity profiles. 
Monitoring the position of Phe8 of AngII within the binding pocket revealed that 
[Sar1Hcy3,5]AngII is at a disadvantage when compared to AngII to insert the aromatic 
sidechain of Phe8 within the hydrophobic core. This could explain the reduced potency and 
efficacy of [Sar1Hcy3,5]AngII on the Gq pathway. The importance of Phe8 of AngII for Gq-
mediated signaling is well documented and we have previously linked its insertion within 
the hydrophobic core to the activation of the Gq pathway [19,37,40]. The data obtained in 
the current study suggest that the energy barrier that needs to be overcome for the insertion 
of Phe8 in the hydrophobic core is increased in [Sar1Hcy3,5]AngII compared to AngII, 
possibly due to the conformational restriction imposed by the disulfide bond. This barrier 
also appears increased for AngII and [Sar1Ile8]AngII when these linear ligands adopt a g-
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turn conformation (similar to the cyclic ligand) compared to the extended conformation. 
Thus, when compared to the β-strand and extended conformations, the g-turn conformation 
of AngII, to which the cyclic analog is confined, is less effective at stabilizing the Gq-
active state.  
It must be stressed that in our simulations, the transition of the Phe8 residue from 
the exterior to the interior the hydrophobic core essentially occurred only with AngII, as 
the starting configurations of simulation #C1 and #C3 were generated from simulations of 
AngII in which it adopted a conformation compatible with the cyclic ligand. Because all 
simulations started with the ligand positioned within the binding pocket, the actual process 
of ligand binding has been bypassed, which nullifies our ability to sample potential events 
of conformational selection that occurs before the ligand binds the receptor. Further MD 
simulations will be required to better evaluate the binding and stabilization of the different 
states of the receptor by the ligands. Furthermore, residue Phe8 interacts directly with the 
side-chain of the conserved residue W2536.48, the “tryptophan toggle switch”, which has 
been identified as important for G protein-mediated signaling by several GPCRs but shown 
to be of little importance for inositol phosphate production by the AT1R [41,42]. Its role in 
the activation of other pathways by the AT1R is to be determined. Likewise, another 
potentially conserved switch in GPCR activation, F2496.44, is located just one helix turn 
below W2536.48 but its role in AT1R-mediated signaling is currently unclear. Further work 
is required to identify and characterize how these potential switches affect AT1R signaling 
and the conformational landscape explored by the receptor. The mildly biased 
[Sar1Hcy3,5]AngII ligand should prove to be a useful tool for this endeavor as it 
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complements the unbiased ligand AngII and the strongly biased ligand [Sar1Ile8]AngII, 
which is completely inactive on the Gq pathway.  
In conclusion, our results suggest that constraining AngII through a linkage 
between positions 3 and 5 by Hcy disulfide bond leads to a local γ-turn conformation that 
introduces a Gq pathway negative bias while retaining full agonism for all other pathways. 
This opens up new strategies in order to develop new biased non-peptidic analogs of the 
AT1R that could serve in more targeted treatment and furthers our understanding of the 
AT1R activation process.  
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FIGURE 
 
Fig. 1. Activation of AT1R signalling pathways by AngII analogs. For all assays, cells 
were stimulated with increasing concentrations of AngII, [Sar1Hcy3,5]AngII, 
[Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII  for the indicated times. (A) HEK293 cells 
expressing the AT1R were stimulated for 30 min at 37°C. IP1 accumulation was measured 
with the IP-One assay, as described in the methods. (B) HEK293 cells co-transfected with 
AT1R, Gα12-RLucII, Gγ1-GFP10 and Gβ1 were stimulated for 8 min at 37°C. G12 activity 
was measured as described in the methods. (C, D) HEK293 cells co-transfected with AT1R, 
Gαi2-RLucII (C) or Gαi3-RLucII (D), Gγ2-GFP10 and Gβ1 were stimulated for 1 min at 
37°C. (E) HEK293 cells co-transfected with AT1R, Gαz-RLucII, Gγ1-GFP10 and Gβ1 
were stimulated for 5 min at 37°C. (F, G) HEK293 cells co-transfected with fusion protein 
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RLucII-βarr1 (F) or RLucII-βarr2 (G) together with AT1R-GFP10 were stimulated for 8 
min at 37°C. βarr recruitment was measured as described in the methods. (H) HEK293 
cells expressing the AT1R were pretreated with 250 nM PD168393 for 30 min and then 
were stimulated for 2 min at 37°C. ERK activity was measured as described in the methods. 
(I)  HEK293 cells expressing the AT1R were pretreated with 1 uM Go6983 for 30 min and 
then were stimulated for 5 min at 37°C. ERK activity was measured as described in the 
methods. Data are expressed as a percentage of AngII maximal response. Data are the mean 
± SD of 3-6 independent experiments performed in triplicate. 
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Fig. 2. Effects of AngII analogs on AT1R signaling pathways. Radar graph 
representations summarizing the calculated Δlog(t/KA) values of the different ligand-
activated pathways  [Sar1Hcy3,5]AngII (A), [Sar1Cys3Hcy5]AngII (B) and 
[Sar1Cys3,5]AngII (C). The balanced reference analog AngII is represented in blue.  
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Fig. 3. (A) 3D representation of the three cyclic analogs: [Sar1Hcy3,5]AngII, 
[Sar1Cys3Hcy5]AngII and [Sar1Cys3,5]AngII. Arrows indicate the Cβ atoms of residues 
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in positions 3 and 5. (B) Probability distribution of the distance between the Cβ atoms of 
residues in positions 3 and 5 of the cyclic peptides in water measured from 10 ns MD 
simulations.  
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Fig. 4. Probability distribution of the distance between the Cβ atoms of residues in 
positions 3 and 5 for ligands in complex with AT1R measured from 1 µs MD 
simulations. (A) AngII-AT1R, AngII-AT1R (5 µs) and [Sar1Ile8]AngII-AT1R. (B) 
[Sar1Hcy3,5]AngII-AT1R (#C1, #C2 and #C3) and the corresponding control simulations 
with AngII-AT1R (#L1, #L2 and #L3). The arrows indicate the initial distance at the start 
of each MD simulation. The initial distance was the same for all three simulations in (A). 
Each simulation is composed of the trajectories of 100 ns in length. 
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Fig. 5. Examples of the β-strand, γ-turn and extended conformations of AngII. The β-
strand and γ-turn conformations shown are snapshots taken from MD simulations of the 
AngII-AT1R complex. The extended conformation was manually generated for comparison 
purpose. Carbon atoms are colored gray, except for residues Val3 and Ile5 which are colored 
green. Oxygen atoms are red, nitrogen atoms are blue and polar hydrogens are white. 
  
This is the postprint version of the following article: St-Pierre D, et al. (2018), Biochem 
Pharmacol. doi: 10.1016/j.bcp.2018.04.021, which has been accepted and published in 
final form at https://www.sciencedirect.com/science/article/pii/S0006295218301643  
46 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
 
Fig. 6. Snapshots from the MD simulation of the AngII-AT1R complex showing the 
positioning of Phe8 of AngII outside of the AT1R hydrophobic core, further from 
residue F772.53 (A) and inside the hydrophobic core, closer to residue F772.53 (B). 
Transmembrane domains are shown as colored ribbons and colored differently from blue 
(TM1) to red (TM7). The backbone of AngII is shown as a grey ribbon. The sidechains of 
Phe8 and F772.53 are shown as sticks. Sidechains from residues forming the hydrophobic 
core are shown as semi-transparent spheres. 
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Fig. 7. Probability distribution of the distance between the side chain of residue Phe8 
of the ligand and the side chain of residue F772.53 of the AT1R measured from 1 µs 
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MD simulations. (A) AngII-AT1R, AngII-AT1R (5 µs) and [Sar1Ile8]AngII-AT1R. (B) 
[Sar1Hcy3,5]AngII-AT1R (dashed lines, simulations #C1, #C2 and #C3) and the 
corresponding control simulations with AngII-AT1R (bold lines, simulations #L1, #L2 and 
#L3. (C) Sum of the individual simulations shown in (B), adjusted to represent the same 
cumulative probability. 
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Fig. 8. 2D probability landscapes generated by sorting frames of the MD simulations. 
(X axis) Distance between the side chain of residue Phe8 of the ligand and the side chain 
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of residue F772.53 of the AT1R. The vertical grey line is positioned approximately on the 
transition state at d  = 0.88 nm as a visual aid. Populations to the left of this line are in the 
hydrophobic core, and those to the right of this line are outside the hydrophobic core. (Y 
axis) Distance between the Cβ atoms of residues in positions 3 and 5 of AngII or [Sar1, 
Hcy3,5]AngII. The horizontal grey line is positioned at d = 0.70 nm and represents the β-
strand conformation of the ligand as a visual aid. Populations above this line have their 
ligand in the extended conformation, and those below this line have their ligand in the γ-
turn conformation. The 2D probability landscapes shows AngII-AT1R, AngII-AT1R (5 µs) 
and [Sar1Ile8]AngII-AT1R (first row). #C1, #C2 and #C3 represents different 
conformations of the [Sar1Hcy3,5]AngII-AT1R complex (second row) and #L1, #L2 and 
#L3 represents different conformations of the control AngII-AT1R complex (third row). 
  
This is the postprint version of the following article: St-Pierre D, et al. (2018), Biochem 
Pharmacol. doi: 10.1016/j.bcp.2018.04.021, which has been accepted and published in 
final form at https://www.sciencedirect.com/science/article/pii/S0006295218301643  
51 
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Table 1 
Binding properties of AT1R ligands  
 Kd (nM) n 
AngII 0.9 ± 0.3 15 
[Sar1Hcy3,5]AngII 2.7 ± 1.3 3 
[Sar1Cys3Hcy5]AngII 324 ± 128 3 
[Sar1Cys3,5]AngII 674 ± 155 3 
 
HEK293 cells stably expressing the AT1R were assayed as described in the methods. 
Binding affinities (Kd) are expressed as the means ± SD of values obtained in n 
independent experiments performed in duplicate.  
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Table 2 
Activation of Gq, Gi2, Gi3, Gz, βarr1, βarr2, G12, PKC-ERK and EGFR-ERK by AT1R 
ligands  
 
 
AngII 
[Sar1Hcy3,5]AngI
I 
[Sar1Cys3Hcy5]AngI
I 
[Sar1Cys3,5]AngI
I 
 
EC50 
(nM
) 
Emax  
(% 
AngII
) 
EC50 
(nM) 
Emax  
(% 
AngII) 
EC50 (nM) 
Emax  
(% 
AngII) 
EC50 
(nM) 
Emax  
(% 
AngII) 
Gq/11 3.9 ± 
1.5 
100 51 ± 
13** 
78 ± 6 1565 ± 
636*** 
70 ± 5 2922 ± 
305*** 
60 ±9 
Gi2 2.2 ± 
0.7 
100 3.7 ± 
1.6 
102 ± 
14 
92 ± 32** 64 ± 6 58 ± 
34** 
53 ± 8 
Gi3 1.5 ± 
0.5 
100 2.5 ± 
1.5 
109 ± 
20 
62 ± 21** 92 ± 20 67 ± 
19** 
73 ± 
24 
Gz 5.6 ± 
2.6 
100 7.4 ± 
3.8 
97 ± 14 29 ± 5 70 ± 12 18 ± 7 64 ± 
12 
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βarr1 4.1 ± 
0.9 
100 4.9 ± 
1.3 
97 ± 2 183 ± 
42*** 
46 ± 10 891 ± 
155*** 
53 ± 9 
βarr2 3.3 ± 
1.3 
100 4.7 ± 
1.0 
100 ± 2 222 ± 
67*** 
70 ± 2 980 ± 
82*** 
61 ± 8 
G12 6.6 ± 
3.7 
100 8.0 ± 
4.6 
101 ± 6 125 ± 47* 37 ± 9 949 ± 
475** 
42 ± 
17 
PKC-
ERK 
4.8 ± 
1.6 
100 13 ± 5 107 ± 7 234 ± 
59*** 
72 ± 3 280 ± 
16*** 
55 ± 4 
EGFR
-ERK 
3.2 ± 
0.7 
100 10 ± 
1** 
99 ± 9 299 ± 
30*** 
85 ± 4 187 ± 
40*** 
62 ± 9 
*p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001 compared to AngII in a Kruskal-Wallis multiple 
comparison test followed by a Dunn’s post-hoc test. 
 
HEK293 cells expressing the AT1R were assayed as described in the methods. EC50 and 
Emax are expressed as the means ± SD of values obtained in at least 3 independent 
experiments performed in triplicate. 
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Table 3 
Transduction ratios of AT1R ligands 
 AngII [Sar1Hcy3,5]AngII [Sar1Cys3Hcy5]AngII [Sar1Cys3,5]AngII 
 log(t/KA) Δlog(t/KA
) 
log(t/KA) Δlog(t/KA
) 
log(t/KA) Δlog(t/KA
) 
log(t/KA) Δlog(t/KA
) 
Gq/11 8.49 ± 
0.11 
0.00 ± 
0.16 
6.79 ± 
0.08 
-1.70 ± 
0.14 
5.45 ± 
0.11 
-3.05 ± 
0.16 
4.76 ± 
0.19 
-3.74 ± 
0.22 
Gi2 8.84 ± 
0.33 
0.00 ± 
0.47 
8.36 ± 
0.26 
-0.48 ± 
0.42 
5.87 ± 
0.19 
-2.97 ± 
0.39 
5.30 ± 
0.25 
-3.54 ± 
0.42 
Gi3 8.97 ± 
0.28 
0.00 ± 
0.39 
8.98 ± 
0.13 
0.01 ± 
0.30 
7.18 ± 
0.12 
-1.78 ± 
0.30 
6.62 ± 
0.20 
-2.35 ± 
0.34 
Gz 8.34 ± 
0.23 
0.00 ± 
0.32 
8.29 ± 
0.10 
-0.05 ± 
0.25 
6.34 ± 
0.14 
-2.00 ± 
0.27 
6.46 ± 
0.22 
-1.88 ± 
0.32 
βarr1 8.39 ± 
0.07 
0.00 ± 
0.10 
8.25 ± 
0.08 
-0.14 ± 
0.11 
5.14 ± 
0.22 
-3.25 ± 
0.23 
5.08 ± 
0.11 
-3.31 ± 
0.13 
βarr2 8.39 ± 
0.09 
0.00 ± 
0.12 
8.33 ± 
0.04 
-0.06 ± 
0.10 
6.15 ± 
0.09 
-2.24 ± 
0.12 
5.28 ± 
0.10 
-3.11 ± 
0.14 
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G12 8.14 ± 
0.17 
0.00 ± 
0.25 
8.14 ± 
0.14 
0.01 ± 
0.22 
4.84 ± 
0.26 
-3.30 ± 
0.31 
5.21 ± 
0.21 
-2.92 ± 
0.28 
PKC-ERK 8.32 ± 
0.08 
0.00 ± 
0.12 
7.92 ± 
0.11 
-0.40 ± 
0.14 
6.27 ± 
0.21 
-2.10 ± 
0.22 
5.63 ± 
0.09 
-2.70 ± 
0.12 
EGFR-ERK 8.59 ± 
0.03 
0.00 ± 
0.05 
7.97 ± 
0.09 
-0.62 ± 
0.09 
6.22 ± 
0.05 
-2.37 ± 
0.06 
5.80 ± 
0.45 
-2.79 ± 
0.45 
 
HEK293 cells expressing the AT1R were stimulated with the different analogs and 
responses were measured for 9 distinct signaling pathways. Data were analysed by 
nonlinear regression using the Operational Model equation as described in the methods to 
determine log(t/KA). Δlog(t/KA) were calculated from log(t/KA) using AngII as the 
reference ligand. Data are the mean ± SEM of 3-6 independent experiments performed in 
triplicate. 
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Table 4 - Bias factors of AT1R ligands - G proteins vs βarrestin 
 AngII [Sar1Hcy3,5]-AngII [Sar1Cys3Hcy5]-
AngII 
[Sar1Cys3,5]-AngII 
 ΔΔlog(t/KA
) 
BF ΔΔlog(t/KA
) 
BF ΔΔlog(t/KA) BF ΔΔlog(t/KA
) 
BF 
βarrestin1 /Gq/11 0.00 ± 0.19 1.00 1.56 ± 
0.17*** 
36.10 -0.21 ± 0.28 0.62 0.43 ± 0.26 2.67 
βarrestin2/Gq/11 0.00 ± 0.20 1.00 1.65 ± 
0.17*** 
44.29 0.81 ± 0.20 6.42 0.63 ± 0.26 4.23 
G12/Gq/11 0.00 ± 0.29 1.00 1.71 ± 
0.26*** 
50.99 -0.25 ± 0.35 0.56 0.81 ± 0.35 6.53 
Gi2/ Gq/11 0.00 ± 0.50 1.00 1.22 ± 0.45  16.47 0.08 ± 0.42 1.20 0.19 ± 0.47 1.56 
Gi3/ Gq/11 0.00 ± 0.39 1.00 1.71 ± 0.30 51.38 1.26 ± 0.30 18.3
8 
1.39 ± 0.34 24.28 
Gz/ Gq/11 0.00 ± 0.36 1.00 1.65 ± 0.28 44.93 1.04 ± 0.31 11.0
8 
1.85 ± 0.39 71.48 
βarrestin2/ G12 0.00 ± 0.28 1.00 -0.06 ± 0.24 0.87 1.06 ± 0.34 11.4
0 
-0.19 ± 0.31 0.65 
βarrestin1/ G12 0.00 ± 0.27 1.00 -0.15 ± 0.25 0.71 0.04 ± 0.39 1.10 -0.39 ± 0.30 0.41 
βarrestin2/ βarrestin1 0.00 ± 0.16 1.00 -0.09 ± 0.14 0.82 -1.02 ± 
0.27** 
0.10 -0.20 ± 0.19 0.63 
Gi2/ βarrestin1 0.00 ± 0.48 1.00 -0.34 ± 0.44 0.46 0.29 ± 0.45 1.93 -0.24 ± 0.44 0.58 
Gi3/ βarrestin1 0.00 ± 0.41 1.00 0.15 ± 0.32 1.42 1.47 ± 0.38 29.6
2 
0.96 ± 0.37 9.08 
Gz/ βarrestin1 0.00 ± 0.34 1.00 0.10 ± 0.27 1.24 1.25 ± 0.36 17.8
6 
1.43 ± 0.34 26.73 
Gi2/ βarrestin2 0.00 ± 0.49 1.00 -0.43 ± 0.43 0.37 -0.73 ± 0.41 0.19 -0.43 ± 0.44 0.37 
Gi3/ βarrestin2 0.00 ± 0.41 1.00 0.06 ± 0.32 1.16 0.46 ± 0.33 2.86 0.76 ± 0.37 5.73 
Gz/ βarrestin2 0.00 ± 0.35 1.00 0.01 ± 0.27 1.01 0.24 ± 0.30 1.72 1.23 ± 0.34 16.88 
Gi2/ G12 0.00 ± 0.53 1.00 -0.49 ± 0.48 0.32 0.33 ± 0.50 2.12 -0.62 ± 0.50 0.37 
Gi3/ G12 0.00 ± 0.46 1.00 0.00 ± 0.38 1.01 1.51 ± 0.44 32.6
3 
0.57 ± 0.44 5.73 
Gz/ G12 0.00 ± 0.41 1.00 -0.05 ± 0.34 0.88 1.29 ± 0.41 19.6
7 
1.04 ± 0.42 16.88 
Gi3/ Gi2 0.00 ± 0.61 1.00 0.49 ± 0.52 3.12 1.19 ± 0.49 15.3
6 
1.19 ± 0.54 0.24 
Gz/ Gi2 0.00 ± 0.57 1.00 0.44 ± 0.49 0.37 0.97 ± 0.47 9.26 1.66 ± 0.52 3.72 
Gi3/ Gz 0.00 ± 0.51 1.00 0.06 ± 0.39 1.14 0.22 ± 0.41 1.66 -0.47 ± 0.47 10.95 
 
ΔΔlog(t/KA) and BF values were calculated as described in the methods. Data are the mean 
± SEM of 3-6 independent experiments performed in triplicate. ** P < 0.01 and *** P < 
0.001 in a Two-tailed unpaired t-test. 
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Table 5 - Bias factors of AT1R ligands – ERK signaling pathways 
 AngII [Sar1Hcy3,5]-AngII [Sar1Cys3Hcy5]-
AngII 
[Sar1Cys3,5]-AngII 
 ΔΔlog(t/KA
) 
BF ΔΔlog(t/KA
) 
BF ΔΔlog(t/KA) BF ΔΔlog(t/KA
) 
BF 
PKC-ERK/βarrestin2 0.00 ± 0.17 1.00 -0.35 ± 0.17 0.45 0.18 ± 0.26 1.52 0.41 ± 0.18 2.60 
PKC-ERK/βarrestin1 0.00 ± 0.15 1.00 -0.26 ± 0.17 0.55 1.20 ± 0.32** 15.7
6 
0.61 ± 0.18 4.11 
EGFR-
ERK/βarrestin2 
0.00 ± 0.13 1.00 -0.56 ± 0.13 0.27 -0.13 ± 0.14 0.74 0.32 ± 0.47 2.10 
EGFR-
ERK/βarrestin1 
0.00 ± 0.11 1.00 -0.47 ± 0.14 0.34 0.88 ± 0.24** 7.64 0.52 ± 0.47 3.33 
PKC-ERK/G12 0.00 ± 0.27 1.00 -0.41 ± 0.26 0.39 1.24 ± 0.39 17.3
6 
0.23 ± 0.30 1.68 
EGFR-ERK/G12 0.00 ± 0.25 1.00 -0.62 ± 0.24 0.24 0.93 ± 0.32 8.42 0.13 ± 0.53 1.36 
PKC-ERK/EGFR-
ERK 
0.00 ± 0.12 1.00 0.21 ± 0.17 1.64 0.31 ± 0.23 2.06 0.09 ± 0.47 1.24 
PKC-ERK/Gq/11 0.00 ± 0.19 1.00 1.30 ± 
0.19*** 
19.90 0.99 ± 0.27 9.78 1.04 ± 
0.25** 
10.99 
EGFR-ERK/Gq/11 0.00 ± 0.16 1.00 1.08 ± 
0.17*** 
12.13 0.68 ± 0.17 4.74 0.95 ± 0.51 8.90 
Gi2/ PKC-ERK 0.00 ± 0.49 1.00 -0.08 ± 0.45 0.83 -0.91 ± 0.45 0.12 -0.85 ± 0.44 0.14 
Gi3/ PKC-ERK 0.00 ± 0.41 1.00 0.41 ± 0.33 2.58 0.27 ± 0.38 1.88 0.34 ± 0.36 2.21 
Gz/ PKC-ERK 0.00 ± 0.34 1.00 0.35 ± 0.28 2.26 0.05 ± 0.35 1.13 0.81 ± 0.34 6.51 
Gi2/ EGFR-ERK 0.00 ± 0.48 1.00 0.13 ± 0.43 1.36 -0.60 ± 0.39 0.25 -0.76 ± 0.62 0.17 
Gi3/ EGFR-ERK 0.00 ± 0.39 1.00 0.63 ± 0.32 4.24 0.59 ± 0.31 3.87 0.44 ± 0.57 2.73 
Gz/ EGFR-ERK 0.00 ± 0.33 1.00 0.57 ± 0.27 3.70 0.37 ± 0.28 2.34 0.90 ± 0.55 8.04 
 
ΔΔlog(t/KA) and BF values were calculated as described in the methods. Data are the 
mean ± SEM of 3-6 independent experiments performed in triplicate. ** P < 0.01 and 
*** P < 0.001 in a Two-tailed unpaired t-test.  
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Table 6 
Rank order of potency of AngII and macrocyclic analogues on affinity and signaling 
pathways 
Affinity AngII > [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII > [Sar1Cys3,5]AngII 
IP-One AngII > [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII > [Sar1Cys3,5]AngII 
Gi2 AngII = [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII > [Sar1Cys3,5]AngII 
Gi3 AngII = [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII > [Sar1Cys3,5]AngII 
Gz AngII = [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII = [Sar1Cys3,5]AngII 
βarr1 AngII = [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII = [Sar1Cys3,5]AngII 
βarr2 AngII = [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII > [Sar1Cys3,5]AngII 
G12 AngII = [Sar1Hcy3,5]AngII > [Sar1Cys3,5]AngII > [Sar1Cys3Hcy5]AngII 
PKC-ERK AngII > [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII > [Sar1Cys3,5]AngII 
EGFR-ERK AngII > [Sar1Hcy3,5]AngII > [Sar1Cys3Hcy5]AngII > [Sar1Cys3,5]AngII 
 
Rank order of potency was determined based on Ki values for affinity and on the log(t/KA) 
for the signaling pathways. 
 
 
